Clinical validation of Lumipulse G1200 automated immunoassays for Alzheimer's disease biomarkers in a Quebec cohort
Lumipulse G1200 immunoassays showed excellent agreement with amyloid and tau PET. Their ease of use and high diagnostic accuracy make them strong candidates for clinical implementation.
Authors
- Chris Hsiao (ORCID: https://orcid.org/0009-0009-2062-3516)
- Nesrine Rahmouni
- Jaime Fernández Arias (ORCID: https://orcid.org/0000-0002-6810-5920)
- Tevy Chan (ORCID: https://orcid.org/0009-0001-9134-5949)
- Yansheng Zheng
- Yi‐Ting Wang
- Lydia Trudel (ORCID: https://orcid.org/0009-0002-5593-7717)
- Arthur Macedo
- Marina P Gonçalves
- Henrik Zetterberg
- Etienne Aumont
- Joseph Therriault
- Andrea Benedet
- Robert Hopewell
- Pedro Rosa‐Neto
- Stijn Servaes
- Paolo Vitali
- Gleb Bezgin
- Kely Monica Quispialaya Socualaya
- Brandon J Hall
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Université du Québec à Montréal (CA)
- University of Pittsburgh (US)
- McGill University Health Centre (CA)
- Profu (Sweden) (SE)
- McGill University (CA)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_107774
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00